$NGNE
Neurogene Inc.

2022 Q2 Form 10-Q Financial Statement

#000162828022013306 Filed on May 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.915M $4.664M $5.414M
YoY Change -7.26% -10.99% 11.63%
% of Gross Profit
Research & Development $10.96M $10.70M $9.760M
YoY Change 11.52% 10.24% 25.29%
% of Gross Profit
Depreciation & Amortization $459.0K $411.0K $390.0K
YoY Change 48.06% 66.4% 85.71%
% of Gross Profit
Operating Expenses $15.87M $10.70M $15.17M
YoY Change 61.55% 10.24% 20.05%
Operating Profit -$15.87M -$15.37M
YoY Change 4.94% 2.79%
Interest Expense $199.0K $14.00K $7.000K
YoY Change 3216.67%
% of Operating Profit
Other Income/Expense, Net -$16.00K $14.00K $0.00
YoY Change 220.0% -800.0%
Pretax Income -$15.69M -$15.35M -$15.17M
YoY Change 3.69% 2.68% 19.99%
Income Tax
% Of Pretax Income
Net Earnings -$15.69M -$15.35M -$15.17M
YoY Change 3.69% 2.68% 19.99%
Net Earnings / Revenue
Basic Earnings Per Share -$0.28 -$0.28
Diluted Earnings Per Share -$284.2K -$0.28 -$275.2K
COMMON SHARES
Basic Shares Outstanding 42.50M shares 55.14M shares 42.43M shares
Diluted Shares Outstanding 55.20M shares 55.14M shares

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $116.5M $128.1M $142.5M
YoY Change -29.09% -28.22% -26.03%
Cash & Equivalents $77.53M $128.1M $142.5M
Short-Term Investments $38.93M $0.00
Other Short-Term Assets $2.028M $2.308M $1.522M
YoY Change -37.81% -20.82% -22.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $118.5M $130.4M $144.0M
YoY Change -29.26% -28.1% -25.98%
LONG-TERM ASSETS
Property, Plant & Equipment $16.50M $6.227M $6.452M
YoY Change 169.88% 21.86% 80.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.020M $1.945M $1.928M
YoY Change 4.55% 1.25% 0.1%
Total Long-Term Assets $18.54M $18.76M $19.27M
YoY Change -5.08% -0.19% 20.49%
TOTAL ASSETS
Total Short-Term Assets $118.5M $130.4M $144.0M
Total Long-Term Assets $18.54M $18.76M $19.27M
Total Assets $137.0M $149.1M $163.3M
YoY Change -26.74% -25.48% -22.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.886M $6.325M $7.415M
YoY Change 23.08% -13.36% 2.99%
Accrued Expenses $1.267M $1.216M $1.166M
YoY Change 18.08% 21.6% 66.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $118.0K $55.00K $55.00K
YoY Change 13.46% -45.0%
Total Short-Term Liabilities $9.271M $7.596M $8.636M
YoY Change 22.24% -9.65% 9.47%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $66.00K $67.00K
YoY Change -85.29% -34.0% -33.0%
Other Long-Term Liabilities $11.03M $11.37M $11.70M
YoY Change -10.31% -9.75% 3.5%
Total Long-Term Liabilities $11.04M $11.44M $11.76M
YoY Change -10.72% -9.94% 3.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.271M $7.596M $8.636M
Total Long-Term Liabilities $11.04M $11.44M $11.76M
Total Liabilities $20.31M $19.03M $20.40M
YoY Change 1.81% -9.95% 5.68%
SHAREHOLDERS EQUITY
Retained Earnings -$408.8M -$393.5M
YoY Change 17.57% 18.24%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $116.7M $130.1M $142.9M
YoY Change
Total Liabilities & Shareholders Equity $137.0M $149.1M $163.3M
YoY Change -26.74% -25.48% -22.45%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$15.69M -$15.35M -$15.17M
YoY Change 3.69% 2.68% 19.99%
Depreciation, Depletion And Amortization $459.0K $411.0K $390.0K
YoY Change 48.06% 66.4% 85.71%
Cash From Operating Activities -$11.29M -$14.09M -$12.17M
YoY Change -14.92% 5.49% 31.83%
INVESTING ACTIVITIES
Capital Expenditures -$232.0K $452.0K -$396.0K
YoY Change -80.5% -58.49% -39.08%
Acquisitions
YoY Change
Other Investing Activities -$39.07M
YoY Change
Cash From Investing Activities -$39.30M -$452.0K -$396.0K
YoY Change 3202.44% -58.49% -39.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 62.00K $133.0K 107.0K
YoY Change -80.19% -52.84% -91.71%
NET CHANGE
Cash From Operating Activities -11.29M -$14.09M -12.17M
Cash From Investing Activities -39.30M -$452.0K -396.0K
Cash From Financing Activities 62.00K $133.0K 107.0K
Net Change In Cash -50.53M -$14.41M -12.46M
YoY Change 257.08% 1.73% 45.02%
FREE CASH FLOW
Cash From Operating Activities -$11.29M -$14.09M -$12.17M
Capital Expenditures -$232.0K $452.0K -$396.0K
Free Cash Flow -$11.06M -$14.54M -$11.77M
YoY Change -8.46% 0.66% 37.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001404644
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-36327
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Neoleukin Therapeutics, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0542593
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
188 East Blaine Street
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 450
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Seattle
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98102
CY2022Q1 dei City Area Code
CityAreaCode
866
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
245-0312
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.000001 par value
CY2022Q1 dei Trading Symbol
TradingSymbol
NLTX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15365000 USD
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42503971 shares
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
128057000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
128000 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1945000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1928000 USD
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142467000 USD
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
2308000 USD
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1522000 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
130365000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
143989000 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6227000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6452000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10516000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10766000 USD
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
73000 USD
CY2022Q1 us-gaap Assets
Assets
149126000 USD
CY2021Q4 us-gaap Assets
Assets
163263000 USD
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6325000 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7415000 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1216000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1166000 USD
CY2022Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
55000 USD
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
55000 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
7596000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8636000 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11371000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11696000 USD
CY2022Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
66000 USD
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
67000 USD
CY2022Q1 us-gaap Liabilities
Liabilities
19033000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
20399000 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42493971 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42493971 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42457471 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42457471 shares
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
538942000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
536362000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-408849000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-393498000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
130093000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
142864000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
149126000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
163263000 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10701000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9707000 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4664000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5241000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14948000 USD
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14000 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15351000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14950000 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55143537 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55143537 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54944421 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54944421 shares
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15351000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14950000 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2446000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2420000 USD
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
411000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
247000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
250000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
265000 USD
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
803000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
813000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-769000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-631000 USD
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-275000 USD
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
104000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14091000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13358000 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
452000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1089000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-452000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1089000 USD
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
134000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
282000 USD
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1000 USD
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
133000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
282000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14410000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14165000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143345000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
193434000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128935000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
179269000 USD
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1584000 USD
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
91000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
794000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
191216000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
282000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2420000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14950000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
178968000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
142864000 USD
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
134000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2446000 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-15351000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
130093000 USD
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
Nature of operationsNeoleukin Therapeutics, Inc. (“Neoleukin” or “the Company”) is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
Use of estimates and assumptionsThe preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, the incremental borrowing rate utilized in the measurement of operating and finance lease liabilities, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical, clinical, and other accruals. Actual results could differ from those estimates.
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42493971 shares
CY2022Q1 us-gaap Security Deposit
SecurityDeposit
900000 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
128057000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142467000 USD
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
878000 USD
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
878000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128935000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143345000 USD
CY2020Q1 nltx Tenant Improvement Allowance
TenantImprovementAllowance
9500000 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10500000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10800000 USD
CY2022Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
200000 USD
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
200000 USD
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42493971 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42457471 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42457471 shares
CY2022Q1 nltx Percentage Of Outstanding Stock Per Stockholder Maximum
PercentageOfOutstandingStockPerStockholderMaximum
0.0999
CY2022Q1 nltx Percentage Of Outstanding Stock Per Stockholder Upon Notice Maximum
PercentageOfOutstandingStockPerStockholderUponNoticeMaximum
0.1999
CY2022Q1 nltx Class Of Warrant Or Right Notice Period
ClassOfWarrantOrRightNoticePeriod
P61D
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2446000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2420000 USD
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
25800000 USD
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M17D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8318
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8968
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y21D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0195
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0061
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8963945 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.20
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M25D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6912000 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
715500 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.46
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
36500 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.67
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1345024 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.52
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8297921 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.60
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M7D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28000 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3341197 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.71
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M17D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0 USD
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
36500 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000 USD
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
91737 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000000 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.75
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.43
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9053182 shares
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7062599 shares

Files In Submission

Name View Source Status
0001628280-22-013306-index-headers.html Edgar Link pending
0001628280-22-013306-index.html Edgar Link pending
0001628280-22-013306.txt Edgar Link pending
0001628280-22-013306-xbrl.zip Edgar Link pending
exhibit3112022q1.htm Edgar Link pending
exhibit3212022q1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nltx-20220331.htm Edgar Link pending
nltx-20220331.xsd Edgar Link pending
nltx-20220331_cal.xml Edgar Link unprocessable
nltx-20220331_def.xml Edgar Link unprocessable
nltx-20220331_htm.xml Edgar Link completed
nltx-20220331_lab.xml Edgar Link unprocessable
nltx-20220331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending